Enlivex Therapeutics Ltd. (ENLV)
ENLV Stock Price Chart
Explore Enlivex Therapeutics Ltd. interactive price chart. Choose custom timeframes to analyze ENLV price movements and trends.
ENLV Company Profile
Discover essential business fundamentals and corporate details for Enlivex Therapeutics Ltd. (ENLV) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
31 Jul 2014
Employees
34.00
Website
https://www.enlivex.comCEO
Oren Hershkovitz
Description
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
ENLV Financial Timeline
Browse a chronological timeline of Enlivex Therapeutics Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Sept 2026
EPS estimate is -$0.30.
Stock split effective on 9 Jul 2026
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Mar 2026
EPS came in at -$3.45 falling short of the estimated -$0.45 by -666.67%.
Earnings released on 25 Mar 2026
EPS came in at $410.25 surpassing the estimated -$1.29 by +31.79k%.
Earnings released on 5 Dec 2025
EPS came in at -$0.12 surpassing the estimated -$1.80 by +93.50%.
Earnings released on 5 Sept 2025
EPS came in at -$2.18 surpassing the estimated -$2.40 by +9.12%.
Earnings released on 13 Jun 2025
EPS came in at -$2.30 surpassing the estimated -$2.40 by +4.09%.
Earnings released on 4 Apr 2025
EPS came in at -$0.24 surpassing the estimated -$2.40 by +90.00%.
Earnings released on 28 Nov 2024
EPS came in at -$0.12 surpassing the estimated -$2.40 by +95.00%.
Earnings released on 6 Sept 2024
EPS came in at -$2.40 falling short of the estimated -$2.25 by -6.67%.
Earnings released on 21 Jun 2024
EPS came in at -$3.30 surpassing the estimated -$3.75 by +12.00%.
Earnings released on 29 Mar 2024
EPS came in at -$0.48 surpassing the estimated -$4.20 by +88.57%.
Earnings released on 4 Dec 2023
EPS came in at -$4.80 matching the estimated -$4.80.
Earnings released on 4 Sept 2023
EPS came in at -$6.00 surpassing the estimated -$6.45 by +6.98%.
Earnings released on 26 Jun 2023
EPS came in at -$5.85 surpassing the estimated -$6.00 by +2.50%.
Earnings released on 31 Mar 2023
EPS came in at -$5.85 falling short of the estimated -$0.38 by -1.44k%.
Earnings released on 5 Dec 2022
EPS came in at -$4.65 falling short of the estimated -$4.35 by -6.90%.
Earnings released on 22 Aug 2022
EPS came in at -$8.10 falling short of the estimated -$6.75 by -20.00%.
Earnings released on 27 May 2022
EPS came in at -$0.55 surpassing the estimated -$6.15 by +91.06%.
Earnings released on 22 Nov 2021
EPS came in at -$0.19 surpassing the estimated -$0.21 by +9.52%.
Earnings released on 9 Aug 2021
EPS came in at -$0.17 surpassing the estimated -$0.26 by +34.62%.
ENLV Stock Performance
Access detailed ENLV performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
